Replies to post #698673 on NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

It is incorrect to say that NICE has to evaluate treatments before they can be marketed. NICE's job is to evaluate the efficacy of a treatment to decide whether it should be included in the NHS's list of treatments that can be prescribed and paid for on the NHS.
If the MHRA licences a treatment but NICE decides that the treatment is too expensive for the benefit provided, patients in the UK will still be able to receive the treatment but they will have to cover the financial costs themselves.